CagriSema (cagrilintide + semaglutide)
Novo's combination of cagrilintide (amylin analog) and semaglutide.
CagriSema is Novo Nordisk's investigational fixed-dose combination of cagrilintide (an amylin analog) and semaglutide (GLP-1 RA). Phase 3 trials show ~22.7% weight loss — competitive with tirzepatide.
Overview
CagriSema combines two distinct mechanisms: semaglutide (GLP-1 RA) plus cagrilintide (a long-acting analog of amylin, a different gut hormone that reduces appetite). The combination is delivered as a single weekly injection. FDA submission expected 2026.
How CagriSema Works
Semaglutide provides standard GLP-1 mechanisms. Cagrilintide adds amylin receptor activation — independent appetite suppression and possibly enhanced satiety. The two work additively.
Dosing & Schedule
Phase 3 used cagrilintide 2.4 mg + semaglutide 2.4 mg weekly.
Effectiveness — Trial Data
REDEFINE-1 (Phase 3, 68 weeks): 22.7% average weight loss vs. 2.3% placebo.
Side Effects
Similar to semaglutide alone with possibly additional amylin-related effects (transient nausea).
Cost — How Much CagriSema Costs in 2026
Not yet on market. Pricing TBD.
Who Is CagriSema For?
Investigational. Likely indications: chronic weight management, type 2 diabetes.
CagriSema Alternatives
Available now: semaglutide, tirzepatide.